Tumour Necrosis Factor Binding Ligands

Abstract

The present invention relates to cell lines that produce ligands that bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms cell lines produce ligands that bind to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.


Claims
Download PDF
Document Preview
Document History
  • Publication: Jun 30, 2009
  • Application: Jun 7, 2007
    US US 75978707 A
  • Priority: Jun 7, 2007
    US US 75978707 A
  • Priority: Jan 5, 2006
    US US 32699606 A
  • Priority: Nov 5, 2003
    US US 70268103 A
  • Priority: Jun 2, 2003
    US US 45317603 A
  • Priority: Feb 7, 2003
    US US 35993403 A
  • Priority: Dec 20, 2002
    US US 32754102 A
  • Priority: Oct 3, 2002
    US US 26545102 A
  • Priority: Dec 13, 2000
    US US 73663000 A
  • Priority: Jul 30, 1999
    US US 36403999 A
  • Priority: Mar 17, 1997
    US US 82389397 A
  • Priority: Nov 23, 1994
    US US 34413394 A
  • Priority: Feb 18, 1992
    US US 82895692 A
  • Priority: Aug 7, 1990
    AU AU 1937/090003 W
  • Priority: Nov 24, 1989
    AU AU PJ757689 A
  • Priority: Aug 7, 1989
    AU AU PJ566289 A

Download Citation


Sign in to the Lens

Feedback